Growth-Hormone Fragment 176–191
Also referenced as: Fragment 176-191, hGH fragment 176-191
A C-terminal growth-hormone fragment discussed in preclinical metabolic research.
- Evidence grade
- DPreclinical Research
Preclinical Research
- Regulatory status
- Research Use Only
Not FDA-approved. Research and sales names do not establish an approved human fat-loss or tissue-repair use.
- Human data
- No
No registered clinical trials identified
- Last reviewed
- October 27, 2026
Overview
A C-terminal growth-hormone fragment discussed in preclinical metabolic research.
Not FDA-approved. Research and sales names do not establish an approved human fat-loss or tissue-repair use.
AOD-9604 is a modified related peptide, often described as Tyr-hGH177–191; similar names do not establish identical chemistry.
Why It's Being Studied
- Growth-hormone fragments
- Preclinical metabolic research
Mechanism of Action
Its structure represents a fragment of growth hormone; claims about selective fat effects require matching the exact sequence studied.
Its structure represents a fragment of growth hormone; claims about selective fat effects require matching the exact sequence studied. AOD-9604 is a modified related peptide, often described as Tyr-hGH177–191; similar names do not establish identical chemistry.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Growth-hormone fragments
- Preclinical metabolic research
- Cell and animal research
Evidence Summary
No convincing human efficacy is established for the unspecified unmodified fragment. AOD-9604 evidence cannot automatically be assigned to it.
Higher tiers carry more weight. Filled tiers have evidence for Growth-Hormone Fragment 176–191; tap to read it.
- No convincing human efficacy is established for the unspecified unmodified fragment. AOD-9604 evidence cannot automatically be assigned to it.
1 cited sources.
- Regulatory document1
Preclinical evidence
- No convincing human efficacy is established for the unspecified unmodified fragment. AOD-9604 evidence cannot automatically be assigned to it.
Reported Adverse Events in Research
- Human safety, immunogenicity and the identity or purity of marketed products remain uncertain.
Limitations of Current Evidence
- AOD-9604 is a modified related peptide, often described as Tyr-hGH177–191; similar names do not establish identical chemistry.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Growth-Hormone Fragment 176–191 | Trofinetide | |
|---|---|---|
| Evidence grade | D — Preclinical Research | B — Moderate Human Evidence |
| Regulatory status | Research Use Only | FDA Approved for Specific Indication |
| Human data | No | Yes |
| Clinical trials | None identified | Registered trials exist |
| Research routes | Cell and animal research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Regulatory document
Growth-Hormone Fragment 176–191 — regulatory document